Benzinga
Benzinga
Benzinga
mercoledì, settembre 30

Aldeyra Therapeutics Inc

ALDXNASDAQ
Trade with Public
Trade with Public
$1.32
0.1613.79%
In chiusura: Sep 28, 5:00 PM EST
$1.33
0.1714.66%
Pre-mercato: 8:03 AM EST
PRO
Perché si muove?:Aldeyra Therapeutics shares are trading higher after the company announced ...
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Aldeyra Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Aldeyra Therapeutics (ALDX).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$7Upside to Avg. PT+445.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 30, 2026HC Wainwright & Co.Matthew CaufieldMaintainedNeutral$2
Sep 29, 2026BTIGThomas ShraderMaintainedBuy$9
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Aldeyra Therapeutics, Maintains $2 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Neutral and maintains $2 price target.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
Benzinga Newsdesk

This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded CF, ALDX, TTD, TME and DUOL. Check their ratings and price targets. Interested in TTD? See what analysts say.
Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2

HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:ALDX) from Buy to Neutral and lowers the price target from $10 to $2.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target

BTIG analyst Thomas Shrader reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $9 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $10 price target.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved